Analyst Day January 17, Alexis Borisy, President and CEO
|
|
- Nathaniel Myles McKinney
- 5 years ago
- Views:
Transcription
1 Analyst Day January 17, 2007 Alexis Borisy, President and CEO
2 2007 CombinatoRx, Incorporated. All rights reserved. 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates and their development and commercial potential, its collaborations, its clinical trials, its formulation efforts, its intellectual property, its financial results and its plans for other research and development programs. These forward-looking statements are based on the current estimates and assumptions of the management of CombinatoRx as of the date of this presentation and are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of CombinatoRx to be materially different from those reflected in such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, the future results of on-going or future clinical trials, the unproven nature of our drug discovery technology, outcomes and timing of the regulatory approval process, our ability to initiate and complete clinical trials, our ability to develop proprietary formulations of our product candidates, the performance under our collaboration agreements and the other risks discussed in this presentation and others that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission, and the other filings made by CombinatoRx with the Securities and Exchange Commission. No forward-looking statement can be guaranteed and actual results may differ materially from those CombinatoRx projects. CombinatoRx is providing this information as of the date of this presentation and does not undertake any obligation to publicly update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law. Today's presentation is not an offer to sell or the solicitation of an offer to buy CombinatoRx common stock.
3 2007 CombinatoRx, Incorporated. All rights reserved. 3 Building CombinatoRx VALUE Synergy = Selective Action The Idea A new approach to drug discovery
4 2007 CombinatoRx, Incorporated. All rights reserved. 4 Building CombinatoRx VALUE Proprietary Technology Renewable and untapped source of drugs The Idea A new approach to drug discovery
5 2007 CombinatoRx, Incorporated. All rights reserved. 5 Building CombinatoRx VALUE 1000 s of Synergies Proprietary Technology Drug Discovery Machine Renewable and untapped source of drugs The Idea A new approach to drug discovery
6 2007 CombinatoRx, Incorporated. All rights reserved. 6 Building CombinatoRx VALUE Technology Partnerships 1000 s of Synergies Proprietary Technology Leverage the Machine Drug Discovery Machine Renewable and untapped source of drugs The Idea A new approach to drug discovery
7 2007 CombinatoRx, Incorporated. All rights reserved. 7 Building CombinatoRx VALUE Multiple POC Clinical Trials Technology Partnerships 1000 s of Synergies Proprietary Technology The Idea Productive Platform Leverage the Machine Drug Discovery Machine Renewable and untapped source of drugs A new approach to drug discovery Introduction of New CRx Products into Clinical Trials * CRx-026 CRx-102 CRx-139 CRx-191 CRx-170 CRx-150 CRx-197 CRx-140 CRx-119 CRx-401 *Planned
8 70% 60% 50% 40% 30% 20% 10% 0% 30% P l a c e b o p = % C R x CombinatoRx, Incorporated. All rights reserved. 8 Building CombinatoRx VALUE % of Patients A chieving AC R20 R espons Advancing the Pipeline Portfolio of Assets Compound Discovery Preclinical Phase 1/2a Phase 2b CRx-102 RA/OA Multiple POC Clinical Trials Productive Platform CRx-170 CRx-139 CRx-150 Chronic Pain RA Immuno-Inflammatory Technology Partnerships Leverage the Machine CRx-026 CRx-191 Multiple Tumors Topical Dermatology 1000 s of Synergies Drug Discovery Machine CRx-197 CRx-401 Preclinical Programs Topical Dermatology Multiple Candidates Diabetes Proprietary Technology Renewable and untapped source of drugs Research: Hepatitis C Huntington s Ophthalmic Cystic Fibrosis Others Multiple Programs The Idea A new approach to drug discovery
9 2007 CombinatoRx, Incorporated. All rights reserved Goals Advance the pipeline with 2 product candidates moving into later-stage clinical development CRx-102 OA and RA CRx-170 Chronic Pain Refresh the pipeline with 3 new product candidates dosed in humans CRx-191 Topical Dermatology CRx-197 Topical Dermatology CRx-401 Type 2 Diabetes Reload late-preclinical pipeline from research engine Introduce next generation product candidates
10 2007 Goals Maintain Financial Strength: 2007 Financial Guidance: Revenue $ M Net Loss $ M* Year-end Cash $ M Partnering strategy * Excluding FAS123 expense 2007 CombinatoRx, Incorporated. All rights reserved. 10
11 2007 CombinatoRx, Incorporated. All rights reserved. 11 CombinatoRx Pipeline: 2007 Compound Discovery Preclinical Phase 1/2a Phase 2b Phase 3 CRx-102 CRx-170 CRx-139 CRx-150 CRx-026 CRx-191 CRx-197 CRx-401 RA/OA Chronic Pain RA Immuno-Inflammatory Multiple Tumors Topical Dermatology Topical Dermatology Diabetes Preclinical Programs Multiple Candidates Research: Hepatitis C Huntington s Ophthalmic Cystic Fibrosis Others Multiple Programs
12 2007 CombinatoRx, Incorporated. All rights reserved. 12 CRx-102 CRx-102* Prednisolone DR Prednisolone IR Dipyridamole XR Synergistic combination of prednisolone and cardiovascular agent Novel mechanism selectively amplifies steroid s desirable activities A combination sciences dissociated steroid Significant activity from an unconventionally low dose of pred (<3mg) 63% ACR20 vs 30% placebo in RA 31% reduction in pain (AUSCAN) vs 7% placebo in OA Advancing into phase 2b trials in RA and OA *Formulation in development
13 Commercial Product CRx-102* Prednisolone DR Prednisolone IR Drug Level Dipyridamole Prednisolone Dipyridamole XR T 0 6hr 12hr 24hr Synergy through sustained co-exposure of components Improved dipyridamole tolerability Once-daily administration Using validated modified-release bead technologies *Formulation in development 2007 CombinatoRx, Incorporated. All rights reserved. 13
14 2007 CombinatoRx, Incorporated. All rights reserved. 14 Goal: A Dissociated Steroid A rapid improvement set in pains and tenderness in the joints abated or disappeared mobility increased patients who had previously been complete invalids could walk about freely Glucocorticoid therapy is very effective at reducing inflammation but chronic use leads to undesirable side effects
15 CRx-102 Mechanism Of Action Synergistically suppresses pro-inflammatory signaling Co-modulates NFkB, AP-1, and NFAT Selective action on trans-repression 2007 CombinatoRx, Incorporated. All rights reserved. 15
16 2007 CombinatoRx, Incorporated. All rights reserved. 16 CRx-102 Clinical Results to Date Study Indication Trial Description Result CRx (POC) Rheumatoid Arthritis 59 subjects, randomized, blinded, moderate RA, 6 weeks, CRx DMARD vs. Placebo + DMARD Significant ACR 20 response, DAS28 and CRP reduction CRx (POC) Osteoarthritis 83 subjects, randomized, blinded, moderate hand OA, 6 weeks, CRx-102 vs. Placebo Significant reduction in pain and stiffness CRx (POM) Inflammatory Biomarker 57 subjects, randomized, blinded, severe periodontitis, 6 weeks, CRx- 102 vs. Placebo Significant reduction in CRP
17 2007 CombinatoRx, Incorporated. All rights reserved. 17 CRx-102: Statistically Significant ACR20 Phase 2a RA Trial CRx DMARD vs. Placebo + DMARD % of Patients Achieving ACR20 Response 70% 60% 50% 40% 30% 20% 10% 0% p= % CRx % Placebo Day 42 % of Patients Achieving ACR20 Response 70% 60% 50% 40% 30% 20% 10% Day of Study CRx-102 Placebo Day 42: p= % *Per Protocol
18 2007 CombinatoRx, Incorporated. All rights reserved. 18 CRx-102: ACR50 and ACR70 Responses Phase 2a RA Trial CRx DMARD vs. Placebo + DMARD ACR50 ACR70 % of Patients Achieving ACR50 Response 30% 25% 20% 15% 10% 5% 0% 15% Placebo p=0.275 (NSS) Day 42 26% CRx-102 % of Patients Achieving ACR70 Response 12% 10% 8% 6% 4% 2% 0% 4% Placebo p=0.368 (NSS) Day 42 11% CRx-102 *Per Protocol
19 CRx-102: Significant DAS28 Response Phase 2a RA Trial CRx DMARD vs. Placebo + DMARD Day of Study Adjusted mean improvement from baseline DAS Placebo CRx p=0.016 Mean Change from Baseline DAS Score Placebo Day 42: p=0.016 CRx-102 Note: Baseline DAS28 scores were 6.9 (CRx-102) and 7.1 (placebo) *Per Protocol 2007 CombinatoRx, Incorporated. All rights reserved. 19
20 2007 CombinatoRx, Incorporated. All rights reserved. 20 CRx-102 Hand OA: Significant Pain Relief Phase 2a OA Trial CRx-102 vs. Placebo Mean percentage improvement from baseline in AUSCAN pain 35% 30% 25% 20% 15% 10% 5% 0% p= % 7% Placebo CRx-102 Day 42 Mean improvement from baseline in AUSCAN pain (mm) p=0.191 (NSS) p=0.010 p=0.023 p=0.006 CRx-102 Placebo Day of Study *Per Protocol
21 2007 CombinatoRx, Incorporated. All rights reserved. 21 Conclusions: CRx-102 in RA and OA Highly positive studies in both RA and OA Result Efficacy in RA Description CRP (-50% vs -19%) p=0.024 ACR20 (63% vs 30%) p=0.025 DAS28 (-1.6 vs -0.7 mean change; -21% vs -10%) p=0.016 Efficacy in hand OA Pain relief (31% vs. 7%) p=0.007 Rapid onset of action Well tolerated Separation seen between 7-14 days No serious adverse events in CRx-102-treated patients Headache and nausea were most common (>5%) adverse events in OA study Headache, GI symptoms, and dizziness were most common (>5%) adverse events in RA study No increases in blood glucose levels or infection rates associated with CRx-102
22 2007 CombinatoRx, Incorporated. All rights reserved. 22 Commercial Opportunities for CRx-102 Immuno-Inflammatory Diseases Rheumatologic Diseases Orphan/Fast track Polymyalgia Rheumatica Osteoarthritis Rheumatoid Arthritis Fibromyalgia TNFα Driven Diseases (IBD, Pulmonary Fibrosis, Psoriasis) CRP Driven Diseases (CAD) Spondyloarthropathies Systemic Lupus Erythematosus Glucocorticoid Sensitive Disease (Asthma, Multiple Sclerosis)
23 CRx-102 RA Opportunities The efficacy and safety profile of CRx-102 may result in multiple viable commercial positions RA Treatment Approach Inadequate Response Initiate Therapy: NSAID Local or Lowdose Systemic Steroids DMARD Add DMARD Methatrexate Other Monotherapy Combination Inadequate Response First-line alternative to steroids or NSAIDS First-line add-on to DMARD Preferred oral add-on to biologic therapy Add Anti-TNF Monotherapy Combination Inadequate Response Try another anti-tnf product Novel Biologics (abatacept, rituximab) Inadequate Response Salvage Therapy Decision Resources May 2006; ACR guidelines 2007 CombinatoRx, Incorporated. All rights reserved. 23
24 2007 CombinatoRx, Incorporated. All rights reserved. 24 CRx-102 OA Opportunities The efficacy and safety profile of CRx-102 may result in a viable alternative for NSAIDs/COXIBs OA Treatment Approach Weight loss and/or exercise Acetaminophen/ paracetamol NSAIDs/ COX-2 inhib. Opioids Intra-articular injections Surgery; Joint replacement CRx-102 Convert NSAIDs/Coxibs Delay/Spare Opioids
25 2007 CombinatoRx, Incorporated. All rights reserved. 25 CRx-102 RA: Planned Trial Design* Stage: Phase 2b Objective: Demonstrate CRx-102 superior to component doses of prednisolone and dipyridamole Subjects: patients (6 arms) Study Design: Randomized, double-blind, controlled; Add-on design Enrollment Criteria: Moderate to severe RA (>4 swollen and >6 tender joints; CRP > upper limit of normal); Concomitant DMARD therapy Treatment: 12 weeks (+ 12 month extension trial) Primary Endpoints: ACR20 (at Week 12) Secondary Endpoints: DAS28, CRP *subject to regulatory approval
26 2007 CombinatoRx, Incorporated. All rights reserved. 26 CRx-102 RA: Planned Trial Schematic* CRx /360 mg CRx /180 mg Prednisolone 2.7 mg Screening Prednisolone 7.5 mg Safety Extension Dipyridamole 360 mg Placebo Day - 28 Day 0 Day 7 Day 28 Day 56 Day 84 (Baseline visit) *subject to regulatory approval
27 2007 CombinatoRx, Incorporated. All rights reserved. 27 CRx-102 Knee OA: Trial Design* Stage: Phase 2b Objective: Demonstrate efficacy of CRx-102 in additional OA target joint (knee) Subjects: patients (5 arms) Study Design: Randomized, double-blind, controlled; Standard flare design: Screening VAS points; Following 1 week NSAID washout, VAS must increase 10 points Primary Comparison: CRx-102 (all doses) to placebo Enrollment Criteria: Radiographic evidence of knee OA; Functional class I, II, III according to the American Rheumatism Association Treatment: 12 weeks (+ 12 month extension trial) Primary Endpoints: Changes in WOMAC pain (baseline to Week 12) Secondary Endpoints: WOMAC stiffness, WOMAC physical function, patient global assessment (VAS) *subject to regulatory approval
28 2007 CombinatoRx, Incorporated. All rights reserved. 28 CRx-102 Knee OA: Planned Trial Schematic* CRx /360 mg CRx /180 mg Screening (wash out NSAIDs) CRx /90 mg Safety Extension Prednisolone 2.7 mg Placebo Day - 7 Day 0 Day 7 Day 28 Day 56 Day 84 (Baseline visit) *subject to regulatory approval
29 2007 CombinatoRx, Incorporated. All rights reserved. 29 CRx-102 Development Status Initiate knee OA phase 2b trial: Mid 2007 Initiate RA CvP trial: 2H07 QD (1x/day) formulation available: 2H07 Initiate clinical comparability study for QD formulation: 1H08 Data from knee OA trial: 2H08 Data from RA trial: 2H08 Data from clinical comparability study: End 2008 Start Phase 3 trials: 1H09
30 2007 CombinatoRx, Incorporated. All rights reserved. 30 CombinatoRx Pipeline: 2007 Compound Discovery Preclinical Phase 1/2a Phase 2b Phase 3 CRx-102 CRx-170 CRx-139 CRx-150 CRx-026 CRx-191 CRx-197 CRx-401 RA/OA Chronic Pain RA Immuno-Inflammatory Multiple Tumors Topical Dermatology Topical Dermatology Diabetes Preclinical Programs Multiple Candidates Research: Hepatitis C Huntington s Ophthalmic Cystic Fibrosis Others Multiple Programs
31 CRx-170 in Chronic Pain CRx-170* Prednisolone DR Nortriptyline CR Synergistic combination of nortriptyline and ultra-low dose steroid Novel dual-action agent Combines analgesic activity of nortriptyline with anti-inflammatory activity of prednisolone Synergy enables low doses and broad therapeutic window Once-daily, night-time formulation for optimal therapeutic benefit Advancing into phase 2 trials in chronic pain *Formulation in development 2007 CombinatoRx, Incorporated. All rights reserved. 31
32 2007 CombinatoRx, Incorporated. All rights reserved. 32 TC + Steroid: Synergistic Combination Class Pro-inflammatory cytokines Steroid Budesonide (um) 0 1.5e-4 6.2e Inhibition (%) DT N=2-4 Average Joint Diameter (mm) In Vivo RA Control Placebo Steroid 3 mg/kg Steroid 0.3 mg/kg TC 5 mg/kg TC/Steroid Mean % Change in Forced Vital Capacity from Baseline 7% 6% 5% 4% 3% 2% 1% 0% Asthma Clinical Trial Mean% Change in Forced Vital Capacity 0.76% 1.04% 5.73% TC Steroid TC/Steroid In Vivo RA Decreased Bone Destruction CRx TC/Steroid Nortriptyline Hydrochloride (um) TC Adjuvant Eosinophils (10^6) in Lung Fluid Days TC + Steroid In Vivo Asthma * 1.5 * 1 * 0.5 Mean Change from Baseline- Response in Injured Paw % Change from Study BL In Vivo Pain % Change from Tx BL mean change from T0 to T1: p-value = Vehicle Diclofenac Steroid 1 mg/kg TC 3 mg/kg TC/Steroid 0 Unchallenged Vehicle Dex 0.3 mg/kg TC 10 mg/kg Steroid 0.3 mg/kg TC/Steroid -30
33 2007 CombinatoRx, Incorporated. All rights reserved. 33 CRx-170: Preclinical Pain Model Synergistic reduction in pain In Vitro In Vivo Nortriptyline Nortriptyline Prednisolone Prednisolone In Vitro TNFa Isobol at 20% inhibition; Pred (.99 um); Nortrip (3.4 um) In Vivo Pain model Isobol at 30 grams retraction force; Pred (.91 mg/kg) Nortrip ( 2.1 mg/kg)
34 Chronic Low Back Pain (CLBP) Pain and disability with episodes lasting > 3 months Prevalence of 30M in major markets (2005) 1 $15B+ in global sales in Tricyclics widely used to treat CLBP Proven activity in multiple randomized controlled trials 2 Anti-depressant use in 10 35% of CLBP patients 1,3 Majority of anti-depressant use from tricyclics Standard dosages of steroid only used intermittently Clear commercial opportunity Convert existing tricyclic prescriptions Capture market share from alternate classes 1 Decision Resources 2006; 3 CombinatoRx market research Dec Salerno et al. (2002); Atkinson et al. (1998) 2007 CombinatoRx, Incorporated. All rights reserved. 34
35 Novel Pharmacology Required CRx-170* Prednisolone DR Nortriptyline CR Plasma [ ] Prednisolone (4-6 h DR) Nortriptyline (CR) 10 pm 3 am 8 am Time *Formulation in development Synergy through co-exposure and optimized timing Builds on traditional tricyclic analgesic use at night plus CR for improved tolerability Prednisolone nocturnal release for optimal activity Using validated modified-release bead technology 2007 CombinatoRx, Incorporated. All rights reserved. 35
36 CRx-170 Chronic Pain: Planned Trial Design* Stage: Phase 2 Objective: Assess the efficacy of CRx-170 for the treatment of chronic low back pain Subjects: Study Design: Randomized, double-blind, placebo/active controlled Primary Comparison: Reduction in pain comparing CRx-170-treated subjects to patients treated with nortriptyline alone Enrollment Criteria: 3 months of low back pain with flare design Study Duration: 8 weeks Primary Endpoints: Pain reduction as measured through a visual analogue scale Secondary Endpoints: Improvement in back-related disability index, reduction of morning symptoms and quality of life assessments *subject to regulatory approval 2007 CombinatoRx, Incorporated. All rights reserved. 36
37 2007 CombinatoRx, Incorporated. All rights reserved. 37 CRx-170 Development Status Complete formulation development: 2H07 Initiate phase 2 study in CLBP: 2H07 Data from phase 2 study: 2H08
38 2007 CombinatoRx, Incorporated. All rights reserved. 38 CRx-191 Product Candidate Summary CRx-191 Mometasone / Nortriptyline Cream Synergistic combination of mometasone and nortriptyline Novel mechanism amplifies mometasone s desirable activities Target profile is efficacy of high-potency steroid, safety of midpotency steroid Novel topical formulation of nortriptyline Advancing into phase 2a trials
39 CRx-191: Psoriasis Market Opportunity Psoriasis prevalence of M US 1 Challenges to topical steroid use in psoriasis Mid-potency steroids well-tolerated, but have limited efficacy High potency steroids effective, but limited by skin atrophy and HPA-axis suppression Strong demand for topical dissociated steroid profile Efficacy of a high-potency steroid with the safety of a mid-potency steroid Potential to extend treatment duration vs. high potency steroid More rapid onset of action vs. mid-potency steroid Multiple expansion opportunities beyond psoriasis Total topical corticosteroid prescription sales > $1B WW 2 across indications 1 NIH, 2 Per-Se Technologies (formerly NDC Health Corporation) March CombinatoRx, Incorporated. All rights reserved. 39
40 2007 CombinatoRx, Incorporated. All rights reserved. 40 Rapid Proof-Of Of-Concept Goal: Demonstrate efficacy similar to high-potency corticosteroid Psoriasis Microplaque Test Up to six arms tested per subject subjects Two week treatment period Quantifiable, validated endpoints Skin thickness (sonography) Infiltrate erythema (chromametry) Clinical assessment
41 2007 CombinatoRx, Incorporated. All rights reserved. 41 CRx-191 Planned Trial Design* Objective Establish CRx-191 efficacy vs. components Design Psoriasis microplaque test Single-center study Double-blind, randomized Primary endpoint: Skin thickness vs. baseline CRx % Mometasone / High % Nortriptyline CRx % Mometasone / Low % Nortriptyline Screening High % Nortriptyline Low % Nortriptyline 0.1% Mometasone Vehicle Day - 7 Day 0 Day 3 Day 7 Day 10 Day 14 (Baseline visit) *subject to regulatory approval
42 2007 CombinatoRx, Incorporated. All rights reserved. 42 CRx-191: Development Status Preclinical toxicology studies in progress Initiate phase 2a trial in plaque psoriasis: Mid 2007 Initiate phase 2a skin atrophy toxicity study: Mid 2007 Data from both phase 2a trials: 2H07 Potential future clinical development in psoriasis and other steroid-responsive dermatoses (pending data)
43 2007 CombinatoRx, Incorporated. All rights reserved. 43 CRx-197 Product Candidate Summary CRx-197 Loratadine / Nortriptyline Cream Synergistic combination of loratadine and nortriptyline Novel mechanism, topical anti-inflammatory Synergistic action on IL-2 and other key cytokines involved in the pathogenesis of atopic dermatitis Novel topical formulations of loratadine and nortriptyline Advancing into phase 2a
44 CRx-197: Atopic Dermatitis Market Opportunity Prevalence: ~15M Atopic Dermatitis patients in the US 1 Significant unmet need Topical corticosteroids (a treatment mainstay) limited by steroidassociated side effects Rapid uptake of topical calcinueurin inhibitors at launch Elidel sales $348M US 2 (2004) following launch in 2001 Protopic sales $200M WW 3 (2004) following launch in 2000 However, Elidel and Protopic use limited by a 2005 FDA health advisory and 2006 black box warning Greater than 40% drop in sales since Continuing significant opportunity for novel MOA topical immunomodulatory agents Source: 1 National Institute of Arthritis and Muscoloskeletal and Skin Dieases, 2 Verispan 2004, 3 Astellas 2005 annual report, 4 Company reports 2005, CombinatoRx, Incorporated. All rights reserved. 44
45 2007 CombinatoRx, Incorporated. All rights reserved. 45 CRx-197 Planned Trial Design* Objective Establish CRx-197 efficacy vs. components Design Psoriasis microplaque test Single-center study Double-blind, randomized Primary endpoint: Skin thickness vs. baseline CRx-197 Loratadine [Dose 1] / Nortriptyline CRx-197 Loratadine [Dose 2] / Nortriptyline Screening CRx-197 Loratadine [Dose 3] / Nortriptyline CRx-197 Loratadine [Dose 4] / Nortriptyline Loratadine Vehicle Day - 7 Day 0 Day 3 Day 7 Day 10 Day 14 (Baseline visit) *subject to regulatory approval
46 2007 CombinatoRx, Incorporated. All rights reserved. 46 CRx-197: Development Status Initiate non-clinical toxicology program: 1H07 Initiate phase 2a trial in plaque psoriasis: 2H07 Data from phase 2a trial: 1H08 Future clinical development targeting atopic dermatitis (pending positive data)
47 CRx-401: Product Candidate Summary CRx-401* Bezafibrate SR Diflunisal IR Synergistic combination of bezafibrate (ex-us dyslipidemia agent) and low-dose diflunisal (analgesic salicylate derivative) Initial preclinical studies suggest novel mechanism with both PPAR and anti-inflammatory activities Demonstrated efficacy in decreasing fasting glucose and insulin resistance comparable to pioglitazone without promoting weight gain in vivo Improves lipid parameters by increasing HDL and decreasing triglycerides Advancing into phase 2a in Type 2 Diabetes *proposed bi-layered formulation in development 2007 CombinatoRx, Incorporated. All rights reserved. 47
48 CRx-401: Bezafibrate Lipid Benefit Bezafibrate is currently a standard of care drug for elevating HDL and reducing triglycerides HDL Triglycerides 25 Pioglitazone Atorvastatin Niacin (ER) Bezafibrate Change in HDL (%) Change in Tg (%) Pioglitazone Atorvastatin Niacin (ER) Bezafibrate -50 Source: Actos (30 mg/d). Package Insert 2004; Lipitor (20mg/d). Package Insert 2004; Niaspan Package Insert (1000 mg/d); Bezalip. Ogawa S. et al. Metabolism. March 2000, 49(3): CombinatoRx, Incorporated. All rights reserved. 48
49 CRx-401: Bezafibrate & Diabetes Bezafibrate also exhibits anti-diabetic properties Decreases fasting plasma glucose modestly in Type 2 diabetic patients and reduces insulin resistance 1 Reduces the incidence and delays the onset of Type 2 diabetes in high risk patients independent of the use of ACE inhibitors, BMI, LDL cholesterol, and triglyceride levels 2,3 Slows decline of beta cell function and increases insulin sensitivity in diabetics 3 Sources: 1 Matsui (1997), Oron-Herman (2005), Jia et al. (2004), Mori et al. (2004), Yuan et al. (2001), Harmon (2001), Pickavance (2005), Kim et al. (2001), Taniguchi et al (2001), Ogawa (2000), Alberti (1990), Mathur (1990), Rovellini (1992), Smud (1997), 2 Circulation May 11;109(18): , 3 Eur Heart J Oct;26(19): CombinatoRx, Incorporated. All rights reserved. 49
50 CRx-401: Preclinical Efficacy The combination of bezafibrate and diflunisal has demonstrated synergistic anti-diabetic benefits in-vitro and in-vivo In Vitro Isobologram Fasting Blood Glucose Insulin Resistance Fractional [ ] 2 Bezafibrate (35uM) Fractional [ ] 2 Diflunsal (100uM) Median Fasting Blood Glucose (mg/dl) Chow Vehicle Pio 6 mg/kg 196 Bez 30 mg/kg 215 DF 50 mg/kg * 182 CRx-401 Median HOMA Score Chow Vehicle Pio 6 mg/kg 20.0 Bez 30 mg/kg 23.2 DF 50 mg/kg * 8.1 CRx-401 High Fat Fed High Fat Fed Data presented in poster format at the American Diabetes Association 66th Scientific Sessions, June 9-13, 2006, Washington, DC. Values: Mean + SEM; * p< 0.05 vs. HFF (ANOVA). Fractional [ ] is fraction of drug concentration achieving 1.5 fold increase in glucose uptake as a single agent 2007 CombinatoRx, Incorporated. All rights reserved. 50
51 CRx-401: Preclinical Efficacy The anti-diabetic benefits are not associated with weight gain Weight Gain Mean % Change in Body Weight Chow Vehicle Pio 10 mg/kg CRx-401 * High Fat Fed Data presented in poster format at the American Diabetes Association 66th Scientific Sessions, June 9-13, 2006, Washington, DC. Values: Mean + SEM; * p< 0.05 vs. Chow (ANOVA) 2007 CombinatoRx, Incorporated. All rights reserved. 51
52 2007 CombinatoRx, Incorporated. All rights reserved. 52 CRx-401: Metabolic Syndrome Through combined insulin, glucose and lipid actions, CRx-401 may offer a novel metabolic syndrome profile Glucose Insulin Resistance Triglyceride HDL LDL Obesity Blood Pressure CRx-401 Development Pipeline GLP-1 Agonists (Byetta, Januvia) Dual PPAR Agonists Fenofibrate + Metformin CETPi Multiple (Acomplia) Current Treatment TZDs TZD+Metformin Metformin Secretagogues Insulin Fibrates Statin + Niacin Statins Orlistat Sibutramine Multiple
53 2007 CombinatoRx, Incorporated. All rights reserved. 53 CRx-401: Market Opportunity The unmet need is substantial and opportunities exist in first line, second line, and custom market segments Market Segment Diagnosed and treated with oral anti-diabetic agents Poorly controlled on existing therapeutics Poorly controlled plus elevated triglycerides and low HDL Market Size ~ 28 MM ~ 10 MM ~ 2.7 MM CRx-401 Market Opportunity Novel MOA for glycemic control Improve lipid profile Weight-neutral Novel MOA to complement standard agents and improve glycemic control Weight-neutral vs glitazones/dual PPARs Improve lipid profile Novel MOA for glycemic control Lower TG and raise HDL to address key patient need Weight-neutral Source: Decision Resources Type 2 Diabetes September 2004: Estimated patient numbers in 2008.Harrison s Principles of Internal Medicine; Alexander et al., Diabetes, Vol. 52, May, 2003, CombinatoRx analysis
54 CRx-401: Planned Trial Design* Stage: Phase 2a Objective: Demonstrate that CRx-401 is superior to bezafibrate alone in lowering fasting plasma glucose Subjects: 80 patients (2 arms) Study Design: Randomized, controlled Primary Comparison: CRx-401 to bezafibrate Enrollment Criteria: Type-2 diabetics who are poorly controlled on metformin Treatment: 12 weeks Primary Endpoints: Changes in fasting plasma glucose Other Measures: HbA1c, Triglycerides, HDL, HOMA-IR, and Weight *subject to regulatory approval 2007 CombinatoRx, Incorporated. All rights reserved. 54
55 2007 CombinatoRx, Incorporated. All rights reserved. 55 CRx-401: Development Status Initiate phase 2a trial in Type 2 diabetes: Mid 2007 Data from phase 2a trial expected: Mid 2008
56 2007 CombinatoRx, Incorporated. All rights reserved. 56 CombinatoRx Pipeline: 2007 Compound Discovery Preclinical Phase 1/2a Phase 2b Phase 3 CRx-102 CRx-170 CRx-139 CRx-150 CRx-026 CRx-191 CRx-197 CRx-401 RA/OA Chronic Pain RA Immuno-Inflammatory Multiple Tumors Topical Dermatology Topical Dermatology Diabetes Preclinical Programs Multiple Candidates Research: Hepatitis C Huntington s Ophthalmic Cystic Fibrosis Others Multiple Programs
57 2007 CombinatoRx, Incorporated. All rights reserved Milestones Program Activity Target CRx-139 Data: Phase 2a, 210 subject, 3 arm, RA trial CRx-150 Data: Phase 2a, 60+ subject, RA trial 1H07 CRx-191 CRx-401 CRx-102 CRx-102 CRx-191 CRx-170 CRx-197 CRx-102 Initiate: Phase 2a topical dermatology (psoriasis) Initiate: Phase 2a type 2 diabetes Initiate: Phase 2b knee OA Initiate: Phase 2b RA Data: Phase 2a topical dermatology (psoriasis) Initiate: Phase 2 chronic lower back pain Initiate: Phase 2a topical dermatology (psoriasis) Complete: QD formulation Mid07 2H07
58 2007 CombinatoRx, Incorporated. All rights reserved Milestones Program Activity Target CRx-197 Data: Phase 2a topical dermatology (psoriasis) CRx-102 Initiate: Clinical comparability study 1H08 CRx-401 Data: Phase 2a type 2 diabetes Mid08 CRx-170 CRx-102 CRx-102 CRx-102 Data: Phase 2 chronic lower back pain Data: Phase 2b knee OA Data: Phase 2b RA Data: Clinical comparability study 2H08
59
Jefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationNYSE AMER: MTNB. MAT9001 OVERVIEW. September 2018
NYSE AMER: MTNB www.matinasbiopharma.com MAT9001 OVERVIEW September 2018 1 Forward Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationProthena Corporation plc
Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationMARINE Study Results
TM MARINE Study Results Nasdaq: AMRN www.amarincorp.com 1 Forward-Looking Statement This presentation contains forward-looking statements, including those relating to the Company s product development
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationInvestor Presentation Post-Interim Results Update. September 2011
Investor Presentation Post-Interim Results Update September 2011 Disclaimer This presentation contains general information about the company s activities current as at 2 September 2011. It is provided
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationANCHOR Study Results Overview
TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company
More informationMedia Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4
More informationZafgen PWS Clinical Trial Program Overview. November 16, 2014
Zafgen PWS Clinical Trial Program Overview November 16, 2014 2 Disclaimers Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information.
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationAmpion TM. Management Presentation 2018
TM Management Presentation 2018 2 Forward-Looking Statement These slides and materials, including any accompanying oral presentation, contain forward-looking statements about our business. You should not
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationMadrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
Madrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial -- Statistically significantly more patients treated with
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationJefferies Healthcare Conference June 8, 2017
Jefferies Healthcare Conference June 8, 2017 1 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationIntercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
July 31, 2017 Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update Worldwide net Ocaliva (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationEli Lilly and Company Investment Community Meeting
Eli Lilly and Company Investment Community Meeting October 3, 2013 8:30 a.m. 12:30 p.m. Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationHalozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. The Next Chapter Begins: Creating Value Through Growth Jefferies 2014 Global Health Care Conference June 2014 Helen Torley, M.B. Ch. B., M.R.C.P. President and Chief Executive
More information34 th Annual JP Morgan Healthcare Conference. January 13, 2016
34 th Annual JP Morgan Healthcare Conference January 13, 2016 SAFE HARBOR Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information.
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationNovan Provides Update on SB414 Inflammatory Skin Disease Development Program
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationAmylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationResults of Phase III Studies of Sitagliptin, new oral treatment of diabetes, were presented by Merck & Co., Inc. at ADA (The 2 nd Announcement)
June 14, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-6272-1001 Results of Phase III Studies of Sitagliptin, new
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationGalvus the most comprehensively studied DPP-4 inhibitor
Galvus the most comprehensively studied DPP-4 inhibitor! >7 000 patients enrolled in clinical studies! >4 00 patients exposed to Galvus >1 300 patients exposed 2 weeks >300 patients exposed for 104 weeks!
More informationHTX-011 Postoperative Pain Program Topline Results From Phase 3. March 19, 2018
HTX-011 Postoperative Pain Program Topline Results From Phase 3 March 19, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationFlexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
May 8, 2018 Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights Company booked net ZILRETTA sales of $2.2 million in Q1 Positive developments in Medicare reimbursement
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Jefferies Global Healthcare Conference June 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationNeedham Healthcare Conference. April 10, 2019
Needham Healthcare Conference April 10, 2019 Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the safe harbor
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationCorporate Presentation. December 2018
Corporate Presentation December 2018 OTCQB: IMNP www.immunepharma.com Forward-Looking Statements This presentation and oral statements made by representatives of the Company may contain projections or
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationAxsome Therapeutics, Inc. AXS-05 R&D Day CNS Pipeline Overview
AXS-05 R&D Day April 24, 2018 Axsome Therapeutics, Inc. AXS-05 R&D Day CNS Pipeline Overview Herriot Tabuteau, MD Chief Executive Officer Axsome Therapeutics, Inc. New York City 3 Forward-Looking Statements
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationJefferies Global Life Sciences Conference June 2010
Jefferies Global Life Sciences Conference June 2010 Cautionary Statement This presentation contains "forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationCompany Update. August 2017
Company Update August 2017 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that
More informationCatabasis Pharmaceuticals Q May 2018
Catabasis Pharmaceuticals Q1 2018 May 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including
More informationADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA
ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA Now Available 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml EWING, N.J., March 29, 2016 Antares Pharma, Inc. (NASDAQ:
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSanthera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone. Webcast, 21 November 2018
Santhera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone Webcast, 21 November 2018 Disclaimer This presentation is not and under no circumstances
More informationEdasalonexent (CAT-1004) Program
Edasalonexent (CAT-1004) Program Oral small molecule designed to inhibit NF-κB for the treatment of Duchenne muscular dystrophy Joanne M. Donovan, MD, PhD Chief Medical Officer, Catabasis Pharmaceuticals
More informationAdvancing Mitochondrial Medicine. Thomas Meier, PhD CEO
Advancing Mitochondrial Medicine Thomas Meier, PhD CEO Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationNexus BioPharma, Inc. Opportunity Overview
Nexus BioPharma, Inc Opportunity Overview Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange
More informationLauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST
Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationEvercore ISI Presentation- Madrigal
Evercore ISI Presentation- Madrigal Forward-Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our clinical studies and our research and development
More informationSosei Group Corporation
Sosei Group Corporation Shinichi Tamura President and CEO www.sosei.com Sosei History - Background Incorporated in Japan in 1990 and traded initially as a technology transfer company In 1999 switched to
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationSeptember 2018 Investor Luncheon. Herriot Tabuteau, MD Chief Executive Officer
NASDAQ: AXSM September 2018 Investor Luncheon Herriot Tabuteau, MD Chief Executive Officer 2018, Axsome Therapeutics, Inc. FLS Forward-Looking Statements & Safe Harbor Certain information contained in
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationCompany Overview. September 2018 NASDAQ: MDGL
Company Overview September 2018 NASDAQ: MDGL 1 Forward Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our future financial or business
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More information